Published in J Med Primatol on August 01, 2007
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol (2008) 1.00
Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology (2009) 0.88
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev (2016) 0.85
Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates. Mol Ther (2015) 0.82
Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. J Med Primatol (2013) 0.81
Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation. Retrovirology (2010) 0.79
Dysregulation of multiple inflammatory molecules in lymph node and ileum of macaques during RT-SHIV infection with or without antiretroviral therapy. J Med Primatol (2014) 0.78
Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. AIDS (2015) 0.77
Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques. Clin Vaccine Immunol (2015) 0.76
Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation. JCI Insight (2017) 0.75
Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of IFN-α. J Virol (2017) 0.75
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
HIV vaccine research: the way forward. Science (2008) 3.86
HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS (2008) 3.42
HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis (2006) 3.09
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr (2007) 2.34
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children. Pediatr Infect Dis J (2004) 2.30
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis (2009) 2.24
Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells (2006) 2.20
Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion (2007) 2.19
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis (2010) 2.12
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 2.10
TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci U S A (2008) 2.09
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08
Why primate models matter. Am J Primatol (2014) 2.05
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05
Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.01
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS (2007) 1.99
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS (2009) 1.87
Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol (2002) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis (2007) 1.75
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis (2004) 1.74
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med (2010) 1.71
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
The strong ion gap predicts mortality in children following cardiopulmonary bypass surgery. Pediatr Crit Care Med (2005) 1.68
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64
Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis (2004) 1.61
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis (2009) 1.57
Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol (2005) 1.57
Mid-term outcomes following endovascular re-intervention for iliac artery in-stent restenosis. Catheter Cardiovasc Interv (2013) 1.56
HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS (2015) 1.55
Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS (2004) 1.55
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
The role of cerebral hyperperfusion in postoperative neurologic dysfunction after left ventricular assist device implantation for end-stage heart failure. J Thorac Cardiovasc Surg (2009) 1.52
Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res (2003) 1.52
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med (2011) 1.51
Heterotrimeric G protein gamma subunits provide functional selectivity in Gbetagamma dimer signaling in Arabidopsis. Plant Cell (2007) 1.51
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
"Early" delayed sternal closure following pediatric cardiac surgery. Ann Thorac Surg (2005) 1.50
Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. MBio (2013) 1.50
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol (2004) 1.49
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease. Environ Health Perspect (2008) 1.45
Validation of the Kenz Lifecorder EX and ActiGraph GT1M accelerometers for walking and running in adults. Appl Physiol Nutr Metab (2008) 1.45
Outcomes following the Kawashima procedure for single-ventricle palliation in left atrial isomerism. Eur J Cardiothorac Surg (2011) 1.43
Sapien 3 Transcatheter Aortic Valve Implantation With Moderate or Without Predilation. J Invasive Cardiol (2016) 1.43
The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am (2007) 1.42
Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention. Catheter Cardiovasc Interv (2013) 1.42
Liaison psychiatry for older people--an overlooked opportunity. Age Ageing (2005) 1.42
Novel TRIM5 isoforms expressed by Macaca nemestrina. J Virol (2007) 1.40
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39
The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev (2010) 1.37
Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. AIDS Res Hum Retroviruses (2008) 1.34
Basic statistical considerations in virological experiments. J Virol (2005) 1.32
The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS (2004) 1.32
Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis (2004) 1.31
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med (2008) 1.28
Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS (2007) 1.28
Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol Bioeng (2009) 1.28
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS (2005) 1.27
Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol (2009) 1.24
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood (2012) 1.22
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ (2005) 1.22
Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry (2003) 1.22